<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2340-9894</journal-id>
<journal-title><![CDATA[Ars Pharmaceutica (Internet)]]></journal-title>
<abbrev-journal-title><![CDATA[Ars Pharm]]></abbrev-journal-title>
<issn>2340-9894</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2340-98942018000200004</article-id>
<article-id pub-id-type="doi">10.30827/ars.v59i2.7516</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Methodology of Gliclazide Detection in Biological Samples]]></article-title>
<article-title xml:lang="es"><![CDATA[Metodología de detección Gliclazida en muestras biológicas]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Merzlikin]]></surname>
<given-names><![CDATA[Serhii I]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Kucher]]></surname>
<given-names><![CDATA[Tetyana V]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Netosova]]></surname>
<given-names><![CDATA[Krystyna Yu]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Kharchenko]]></surname>
<given-names><![CDATA[Dmytro S]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,National University of Pharmacy Drug and Analytical Toxicology Department ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Ukrainian Military Medical Academy  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2018</year>
</pub-date>
<volume>59</volume>
<numero>2</numero>
<fpage>85</fpage>
<lpage>90</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2340-98942018000200004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2340-98942018000200004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2340-98942018000200004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[ Aim: This research is dedicated to development of a methodology for the determination of gliclazide in biological samples for analytical diagnostics of lethal overdose caused by the drug.  Materials and Methods: TLC method: chromatographic plates Merck silica gel 60 F254 10×10 cm in size, mobile phase - ethyl acetate, visualization reagent 1% vanillin solution or 5% solution of chloral hydrate. HPLC method: liquid chromatograph «Milichrom-A-02» with UV detecting (RF); Prontosil-120-5-C18-AQ reverse-phase column Ø2×75 mm in diameter, 5 &#956;m grains (Bischoff Analysetechnik und Geräte GmbH, Germany); Gradient elution with a mixture of two eluents (eluent A &#8211; [0.2 M solution LiClO4 &#8211; 0.005 M solution of HClO4] and eluent B - acetonitrile); Wavelength 230 nm.  Results: Methodology for the determination of gliclazide in biological samples is developed. It includes an effective method of gliclazide isolation from the objects of the study, specific and selective chromatographic detection methods and quantitative determination of toxicity in the extracts that had been received. It was established that while using TLC method gliclazide was assigned an Rf value of 0,48±0,01; detection limit is 3.0 &#956;g. When applying HPLC method gliclazide holding time was 7.80 min (RSD = 0.13%), detection limit was 0.050 &#956;g / ml, limit of the quantitative determination was 0.157 &#956;g/ml, linearity of the procedure was in the range of 0.1-20.0 &#956;g/ml. Under the developed conditions, gliclazide was determined at 17.48 ± 1.32 &#956;g/ml (RSD = 6.06%).  Conclusions: Results of the study indicate that methodology for the determination of gliclazide in biological samples that was developed can be used for analytical diagnostics of lethal overdose caused by the drug.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[ Objetivo: Desarrollar un método de detección de gliclazida en muestras biológicas para el diagnóstico analítico de los fallecimientos por sobredosis del fármaco.  Materiales y métodos: Método de CCF: placas para cromatografía Merck silica gel 60 F254 de 10×10 cm de tamaño, fase móvil - acetato de etilo, revelador - solución al 1% de vainillina o solución al 5% de hidrato de cloral. Método de HPLC: cromatógrafo líquido «Milihrom-A-02» con detección de UV (Rusia); columna de fase inversa Prontosil-120-5-C18-AQ de Ø2 x 75 mm, con graneado de 5 mm («Bischoff Analysetechnik und Geräte GmbH», Alemania); elución gradiente con una mezcla de dos eluyentes (eluyente A - [0,2 M solución de LiClO4 - solución de HClO 0,005 M4] y eluyente B - acetonitrilo); la longitud de onda es de 230 nm.  Resultados y discusión: Se desarrolló una metodología de determinación de la gliclazida en muestras biológicos, que incluye un método eficaz de aislar la gliclazida de los objetos de estudio, unos métodos cromatográficos específicos y selectivos de detección y cuantificación de la sustancia tóxica en los extractos obtenidos. Se constató que al aplicarse el método de CCF la gliclazida ha sido identificada de acuerdo con el valor Rf 0,48±0,01; el límite de detección es de 3,0 &#956;g. Al aplicarse el método de HPLC se constató lo siguiente: el tiempo de retención de la gliclazida es de 7,80 min (RSD=0,13%), el límite de detección es de 0,050 &#956;g/ml, el límite de cuantificación es de 0,157 &#956;g/ml, la linealidad del método está en el intervalo de 0,1-20,0 &#956;g/ml. En condiciones diseñadas la gliclazida se detectó a un nivel de 17,48±1,32&#956;g/ml (RSD=6,06%).  Conclusiones: Los resultados obtenidos confirman que la metodología desarrollada de detección de la gliclazida en muestras biológicos es adecuada para el diagnóstico analítico de los fallecimientos por sobredosis del fármaco.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[gliclazide]]></kwd>
<kwd lng="en"><![CDATA[analytical methods of research]]></kwd>
<kwd lng="en"><![CDATA[chemical-toxicological analysis]]></kwd>
<kwd lng="es"><![CDATA[gliclazida]]></kwd>
<kwd lng="es"><![CDATA[métodos analíticos de investigación]]></kwd>
<kwd lng="es"><![CDATA[análisis químico-toxicológico]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pekareva]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advantages Gliclazide MB usage in patients with type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Problems of endocrinology]]></source>
<year>2012</year>
<volume>58</volume>
<page-range>58-61</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smirnova]]></surname>
<given-names><![CDATA[OM]]></given-names>
</name>
<name>
<surname><![CDATA[Kononenko]]></surname>
<given-names><![CDATA[IV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Usage of Diabeton MV in the treatment of type 2 diabetes mellitus and prevention of its late complications]]></article-title>
<source><![CDATA[Pharmateca]]></source>
<year>2011</year>
<volume>16</volume>
<page-range>30-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<source><![CDATA[Side_effects]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kucher]]></surname>
<given-names><![CDATA[TV]]></given-names>
</name>
<name>
<surname><![CDATA[Merzlikin]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Kovalenko]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chromatographic detection of glibenclamide in biological objects in the modeling of combined poisonings with drugs]]></article-title>
<source><![CDATA[Bulletin of Pharmacy]]></source>
<year>2016</year>
<volume>1</volume>
<page-range>28-33</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ruha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lovecchio]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypoglycemia after accidental pediatric sulfonylurea ingestions]]></article-title>
<source><![CDATA[Pediatr Emerg Care]]></source>
<year>2011</year>
<volume>27</volume>
<page-range>846-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gul]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cander]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Girisgin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effectiveness of various doses of octreotide for sulfonylurea-induced hypoglycemia after overdose]]></article-title>
<source><![CDATA[Adv Ther]]></source>
<year>2006</year>
<volume>23</volume>
<page-range>878-84</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kucher]]></surname>
<given-names><![CDATA[TV]]></given-names>
</name>
<name>
<surname><![CDATA[Merzlikin]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Schtrigol]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Investigation of the distribution of glibenclamide in animal organs in the design of acute intoxication]]></article-title>
<source><![CDATA[Science Rise]]></source>
<year>2016</year>
<volume>3</volume>
<page-range>7-12</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kartashov]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
</person-group>
<source><![CDATA[Chemico-toxicological analysis P 1 Isolation of toxic substances from biological objects]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Maikop ]]></publisher-loc>
<publisher-name><![CDATA[Quality Ltd]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
